New Drug Updates in Hematologic Malignancies

This CME/CE/CPE certified activity is jointly provided by

New Drug Updates in Hematologic Malignancies

A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Harborside Medical Education

Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners’ knowledge, competence and performance in both community and academic practice settings.

Release date: January 31, 2019

Expiration date: January 31, 2020

Estimated time to complete activity: .75 hour

Certified for CE by:

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Voice: 760-773-4500
Fax: 760-773-4513
E-mail: contactce@annenberg.net

Journal of the Advanced Practitioner in Oncology

94 North Woodhull Road
Huntington, NY 11743
Voice: 631-692-0800
Fax: 631-692-0805
E-mail: editor@advancedpractitioner.com

© 2019, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

This activity is supported by educational grants from AbbVie Inc., Acerta Pharma, a member of the AstraZeneca Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Faculty

Rebecca Nelson, PharmD, BCOP
Moffitt Cancer Center

Intended Audience

The activity’s target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Harborside Medical Education

Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners’ knowledge, competence and performance in both community and academic practice settings.

Learning Objectives

After completing this educational activity, participants should be able to:

  1. Discuss the pharmacology and indications of medications approved in the year 2017-2018 for the management of patients with hematologic malignancies
  2. Recall the pivotal clinical trial data considered by the FDA when approving new oncologic agents
  3. Identify the signs and symptoms of serious or life-threatening adverse effects of newly approved oncology drugs
  4. Describe the impact of these agents in advanced practice

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.

Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses.Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 0.75 contact hours may be earned for successful completion of this activity

Provider is approved by the California Board of Registered Nursing, Provider No. 13664, for 0.75 contact hours.

Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-19-009-H01-P. This program is designated for up to 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit.

Financial Disclosures

All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Disclosures

Faculty

Dr. Nelson has served on the speaker’s bureau for BTG Inc. Off label use: will discuss venetoclax in combination with decitabine or azacytidine in AML patients.

Annenberg Center for Health Sciences at Eisenhower

Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Lead Nurse Planner

Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has nothing to disclose.

Planners

Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.

Content Reviewers

Christopher Campen, PharmD, BCOP, has served on advisory boards for Agios.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit

Participants who successfully complete this activity—including submission of pre-test, scoring of a minimum of 70% on the learning assessment, and submitting the completed evaluation form—will be able to download a statement of credit.

Course summary
Available credit: 
  • 0.75 ACPE
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Attendance
  • 0.75 CA-BRN
  • 0.75 ANCC
Course opens: 
01/31/2019
Course expires: 
01/31/2020
Cost:
$0.00
Rating: 
0

Available Credit

  • 0.75 ACPE
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Attendance
  • 0.75 CA-BRN
  • 0.75 ANCC

Accreditation Period

Course opens: 
01/31/2019
Course expires: 
01/31/2020

Price

Cost:
$0.00
Please login or register to take this course.